StockData
Atossa Therapeutics, Inc. logo

Atossa Therapeutics, Inc. (ATOS) stock

ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.59−0.16 (-8.86%)

Close on Nov 20, 2026Market cap $15.92MP/E –Yield –

Atossa Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Atossa Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$35.78M. For fiscal 2025 it was -$29.79M. The highest annual figure on record is -$9.07M in fiscal 2018.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.79M–
FY2024Dec 31, 2024-$21.05M–
FY2023Dec 31, 2023-$20.96M–
FY2022Dec 31, 2022-$20.79M–
FY2021Dec 31, 2021-$16.48M–
FY2020Dec 31, 2020-$11.58M–
FY2019Dec 31, 2019-$9.14M–
FY2018Dec 31, 2018-$9.07M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.64M–
Q1 FY2026Mar 31, 2026-$9.58M–
Q4 FY2025Dec 31, 2025-$10.55M–
Q3 FY2025Sep 30, 2025-$6.01M–
Q2 FY2025Jun 30, 2025-$7.26M–
Q1 FY2025Mar 31, 2025-$5.97M–
Q4 FY2024Dec 31, 2024-$7.05M–
Q3 FY2024Sep 30, 2024-$4.76M–
Q2 FY2024Jun 30, 2024-$4.53M–
Q1 FY2024Mar 31, 2024-$4.70M–
Q4 FY2023Dec 31, 2023-$5.57M–
Q3 FY2023Sep 30, 2023-$3.88M–
Q2 FY2023Jun 30, 2023-$4.48M–
Q1 FY2023Mar 31, 2023-$7.02M–
Q4 FY2022Dec 31, 2022-$4.53M–
Q3 FY2022Sep 30, 2022-$5.42M–
Q2 FY2022Jun 30, 2022-$5.95M–
Q1 FY2022Mar 31, 2022-$4.89M–
Q4 FY2021Dec 31, 2021-$3.67M–
Q3 FY2021Sep 30, 2021-$3.07M–
Q2 FY2021Jun 30, 2021-$5.34M–
Q1 FY2021Mar 31, 2021-$4.41M–
Q4 FY2020Dec 31, 2020-$3.43M–
Q3 FY2020Sep 30, 2020-$2.68M–
Q4 FY2019Dec 31, 2019-$2.71M–
Q3 FY2019Sep 30, 2019-$1.77M–
Q4 FY2018Dec 31, 2018-$2.50M–
Q3 FY2018Sep 30, 2018-$2.30M–
Q2 FY2018Jun 30, 2018-$1.83M–
Q1 FY2018Mar 31, 2018-$2.44M–

More Atossa Therapeutics figures

See a number that looks wrong?